Sarepta Therapeutics (SRPT) reported $442.93 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 32.7%. EPS of -$3.58 for the same period compares to $1.50 a year ago.
The reported revenue represents a surprise of +8.42% over the Zacks Consensus Estimate of $408.53 million. With the consensus EPS estimate being -$0.71, the EPS surprise was -404.23%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product, net: $369.61 million compared to the $382.54 million average estimate based on eight analysts. The reported number represents a change of -42.1% year over year.
- Revenues- Product, net- ELEVIDYS: $110 million versus the seven-analyst average estimate of $114.3 million. The reported number represents a year-over-year change of -71.4%.
- Revenues- PMO Products: $259 million compared to the $270.1 million average estimate based on seven analysts. The reported number represents a change of +2% year over year.
- Revenues- Collaboration: $73.33 million versus the seven-analyst average estimate of $25.24 million. The reported number represents a year-over-year change of +262%.
View all Key Company Metrics for Sarepta Therapeutics here>>>
Shares of Sarepta Therapeutics have returned -11% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
